A Closer Look at Democratic VP Choice Harris’s Positions on the 340B Program

A Message from Publisher and CEO Ted Slafsky: Please join us in welcoming AllianceRx Walgreens Prime as the newest 340B Report sponsor. We are very pleased to have them on board. For now, we have more requests for sponsorships than space available. Fortunately, we are creating a new website and newsletter platform that will accommodate our growing group of valued sponsors and allow these great companies to increase their visibility with our loyal readers. More details will be available in the fall but feel free to contact me to make sure you receive future announcements. Reach me at ted.slafsky@340breport.com.

A Closer Look at Democratic VP Choice Harris’s Positions on the 340B Program

While U.S. Sen. Kamala Harris (D-Calif.) has not been one of the most high profile senators on 340B issues, the Democratic vice presidential candidate has not been shy to express her support for the program and challenge the Trump administration’s policies on 340B. Harris, who began serving in the Senate in January 2017, was one of 11 Democratic senators who signed a letter in late 2017 blasting the administration’s foot dragging on a 340B program final regulation that would increase oversight of pharmaceutical manufacturers. Democratic presidential candidate Joe Biden introduced Harris as his running mate yesterday.

.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

×

*Sign up for news summaries and alerts from 340B Report

Site Footer